One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
‘IMpassionate conflicts’ in immunotherapy trials for metastatic triple-negative breast cancer
L.Voorwerk1M.Kok12
Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria
J.J.Gao1D.Krol2P.Narayan2F.Cardoso3M.M.Regan4M.P.Goetz5S.A.Hurvitz6L.Mauro7C.Hodgdon8C.P.Miller2B.Booth2E.Bloomquist2G.Ison2C.Osgood2V.Bhatnagar1L.Fashoyin-Aje12R.Pazdur12L.Amiri-Kordestani2J.A.Beaver12
Important news on nutritional support in cancer patients – but some EFFORT is still ahead: Referring to Bargetzi et al., ‘Nutritional support during hospital stay reduces mortality in patients with different types of cancer: a secondary analysis of a prospective randomized trial’
J.Arends1E.J.Roeland2V.E.Baracos3
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas
S.Schuetze
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines
A.Grothey1M.Fakih2J.Tabernero3
Oncolytic virus in gliomas: a review of human clinical investigations
A.B.Carpenter1A.M.Carpenter2R.Aiken3S.Hanft4
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L.A.Emens1S.Adams2C.H.Barrios3V.Diéras4H.Iwata5S.Loi6H.S.Rugo7A.Schneeweiss8E.P.Winer9S.Patel10V.Henschel11A.Swat12M.Kaul13L.Molinero14S.Patel15S.Y.Chui10P.Schmid16
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
D.Miles1J.Gligorov2F.André3D.Cameron4A.Schneeweiss5C.Barrios6B.Xu7A.Wardley89†D.Kaen10L.Andrade11V.Semiglazov12M.Reinisch13S.Patel14M.Patre15L.Morales15S.L.Patel16M.Kaul14T.Barata17…K.Tabane
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E.P.Mamounas12M.Untch3M.S.Mano4C.-S.Huang5C.E.Geyer Jr16G.von Minckwitz7N.Wolmark18X.Pivot9S.Kuemmel1011M.P.DiGiovanna12B.Kaufman13G.Kunz714A.K.Conlin115J.C.Alcedo16T.Kuehn17I.Wapnir118A.Fontana19J.Hackmann720…S.Loibl730
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D.J.Slamon1P.Neven2S.Chia3G.Jerusalem4M.De Laurentiis5S.Im6K.Petrakova7G.Valeria Bianchi8M.MartÃn9A.Nusch10G.S.Sonke11L.De la Cruz-Merino12J.T.Beck13Y.Ji14C.Wang15U.Deore14A.Chakravartty14J.P.Zarate14…P.A.Fasching16
Nutritional support during the hospital stay reduces mortality in patients with different types of cancers: secondary analysis of a prospective randomized trial
L.Bargetzi12†C.Brack2†J.Herrmann2†A.Bargetzi12L.Hersberger12M.Bargetzi23N.Kaegi-Braun1P.Tribolet14F.Gomes15C.Hoess6V.Pavlicek6S.Bilz7S.Sigrist7M.Brändle7C.Henzen8R.Thomann9J.Rutishauser10D.Aujesky11…P.Schuetz12
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial
A.Le Cesne1J.-Y.Blay2D.Cupissol3A.Italiano4C.Delcambre5N.Penel6N.Isambert7C.Chevreau8E.Bompas9F.Bertucci10L.Chaigneau11S.Piperno-Neumann12S.Salas13M.Rios14C.Guillemet15J.-O.Bay16I.Ray-Coquard2L.Haddag17…S.Foulon1819
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
S.Bellone1D.M.Roque2E.R.Siegel3N.Buza1P.Hui1E.Bonazzoli1A.Guglielmi1L.Zammataro1N.Nagarkatti1S.Zaidi4J.Lee5D.-A.Silasi6G.S.Huang1V.Andikyan1S.Damast1M.Clark1M.Azodi1P.E.Schwartz1…A.D.Santin1
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J.E.Martin1S.Khalife-Hachem1T.Grinda12M.Kfoury23S.Garciaz45F.Pasquier16J.Vargaftig7M.Uzunov8A.Belhabri9S.Bertoli10S.Cotteret11V.Vergé11A.Renneville6F.Rosselli12I.Antony-Debre6E.Rouleau11F.Salviat13O.Caron214…J.B.Micol1614
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials
P.-M.Morice1I.Ray-Coquard2K.N.Moore3V.Diéras4J.Alexandre5
The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients
S.Street1D.Chute2I.Strohbehn2S.Zhao2M.Rengarajan3A.Faje3H.Seethapathy2M.Lee2R.Seethapathy2Z.Drobni45O.Rahma6T.G.Neilan7R.J.Sullivan7A.C.Villani8L.Zubiri9M.J.Mooradian9K.L.Reynolds9M.E.Sise2
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
R.Palich12†M.Veyri3†S.Marot4A.Vozy3J.Gligorov5P.Maingon6A.-G.Marcelin4J.-P.Spano3
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
J.Barrière1E.Chamorey2Z.Adjtoutah3O.Castelnau1A.Mahamat1S.Marco1E.Petit1A.Leysalle4V.Raimondi3M.Carles5
Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor ‘Checkpoint inhibition: protecting against or predisposing for second primary tumors?’ by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs
P.Heudel12S.Chabaud13D.Perol13I.Ray-Coquard12J.-Y.Blay1245
Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays
K.Page1L.J.Martinson1R.K.Hastings1D.Fernandez-Garcia1K.L.T.Gleason2M.C.Gray2A.J.Rushton2K.Goddard2D.S.Guttery1J.Stebbing2R.C.Coombes2J.A.Shaw1
VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)
J.Huober1C.H.Barrios2N.Niikura3M.Jarzab4Y-C.Chang5S.L.Huggins-Puhalla6V.Graupner7D.Eiger7V.Henschel8N.Gochitashvili9C.Lambertini10E.Restuccia7H.Zhang11
VP5-2021: IMpower133: Gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo)
S.V.Liu1T.S.K.Mok2A.S.Mansfield3R.H.De Boer4G.Losonczy5S.Sugawara6M.J.Krzakowski7A.Smolin8M.J.Hochmair9M.C.Garassino10C.M.Gay11J.V.Heymach11L.A.Byers11M.McCleland12B.Y.Nabet12S.Morris13L.Adler13D.Shames12M.Reck14
Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159]
M.R.Mirza1R.L.Coleman2A.González-MartÃn3K.N.Moore4N.Colombo5I.Ray-Coquard6S.Pignata7
Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
K.L.Jhaveri1X.V.Wang2V.Makker3S.-W.Luoh4E.P.Mitchell5J.A.Zwiebel6E.Sharon7R.J.Gray8S.Li8L.M.McShane9L.V.Rubinstein10D.Patton11P.M.Williams12S.R.Hamilton13B.A.Conley14C.L.Arteaga15L.N.Harris14P.J.O’Dwyer16…K.T.Flaherty18
Erratum to ‘Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group’: [Annals of Oncology 30 (2019) 1221–1231]
D.Mandelker1M.Donoghue2S.Talukdar3C.Bandlamudi2P.Srinivasan2M.Vivek45S.Jezdic6H.Hanson3K.Snape3A.Kulkarni7L.Hawkes8J.-Y.Douillard6S.E.Wallace9E.Rial-Sebbag10F.Meric-Bersntam11A.George1213D.Chubb13C.Loveday13…C.Turnbull7131415
